Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CCXI $5.20 0.7800 +17.65%
STML $7.81 1.0200 +15.02%
OMED $14.62 1.0400 +7.66%
ARGS $5.96 0.4000 +7.19%
TGTX $7.73 0.5100 +7.06%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

VRML $1.21 -0.0900 -6.92%
GTXI $0.72 -0.0300 -4.00%
TKMR $4.10 -0.1600 -3.76%
MACK $6.31 -0.2300 -3.52%
IMDZ $12.56 -0.3800 -2.94%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

Myriad Genetics : Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information

(4-traders) May 18, 2016 - Myriad Genetics, Inc. today announced plans to launch a new web portal on that will allow patients to access their personal test results as well as other high-quality tools and ideas to help them make healthcare decisions.
read article 

ASTRO Annual Meeting to Feature Cutting-Edge Cancer Research and Keynotes From Experts in Health Care and Safety

(Yahoo! Finance) May 19, 2016 - Registration opens today for the American Society for Radiation Oncology's (ASTRO) 58th Annual Meeting.
read article 

Big First Move From a Biotech Startup Led By Well-Known Entrepreneur

(Albuquerque Business First) May 18, 2016 - One of Albuquerque's fastest moving new companies notched a significant victory Tuesday.
read article 

Agios Shopped New Cancer Research Program Around Before Partnering With Celgene

(Boston Business Journal/BioFlash blog) May 18, 2016 - Agios Pharmaceuticals shopped around its newly-announced research program on metabolic immuno-oncology to other biotechs before deciding to go with its partner since 2010, Celgene, according to executives.
read article 

ARIAD Announces Pricing and Reimbursement for Iclusig in France

(Yahoo! Finance) May 19, 2016 - ARIAD Pharmaceuticals, Inc. today announced that negotiations with the Economic Committee on Health Care Products in France regarding pricing and reimbursement for Iclusig® (ponatinib) have now concluded.
read article 

8 Stocks on the Move After ASCO Cancer Abstracts

(24/7 Wall St.) May 19, 2016 - 24/7 Wall St. has taken a look at some of the major ASCO movers and how they have performed since the abstracts dropped.
read article 

FDA Grants Profound Medical Corp. IDE Approval for TULSA-PRO™

(Financial Content) May 19, 2016 - Profound Medical Corp., an emerging medical device company focused on prostate care, today announced that it has been granted Investigational Device Exemption ("IDE") approval from the U.S. Food and Drug Administration, for a multicenter Pivotal Clinical Trial.
read article 

Heron and the Never-Ending FDA Drug Review

(TheStreet) May 18, 2016 - Heron Therapeutics won't explain why the FDA is taking so long to render an approval decision for Sustol, the company's lead supportive cancer care drug.
read article 

Celator Pharmaceuticals® Announces VYXEOS™ Granted Breakthrough Therapy Designation

(Celator) May 19, 2016 - FDA awards designation for treatment of adults with therapy-related AML or AML with myelodysplasia-related changes; VYXEOS significantly improved overall survival in a Phase 3 clinical trial.
read corporate press release 

Roche Receives FDA Approval for Novel PD-L1 Biomarker Assay

(SYS-CON Media) May 18, 2016 - The VENTANA PD-L1 (SP142) Assay approved as a complementary diagnostic for TECENTRIQ™ (atezolizumab) immunotherapy.
read article 

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval for People with a Specific Type of Advanced Bladder Cancer

(Genentech) May 18, 2016 - First and only anti-PDL1 cancer immunotherapy approved by the FDA; first FDA-approved treatment for people with a specific type of bladder cancer in more than 30 years.
read corporate press release 

F.D.A. Approves an Immunotherapy Drug for Bladder Cancer

(New York Times) May 18, 2016 - The Food and Drug Administration on Wednesday approved a new immunotherapy drug from Roche to treat bladder cancer, a form of cancer for which there have been no significant new medicines in years.
read article 

Impoverished Background Affects Cancer Risk Later In Life

(Cancer Research UK) May 19, 2016 - A person’s risk of developing some cancers is affected by how they grew up, according to a new report by Cancer Research UK scientists published in the Journal of Epidemiology and Community Health.
read press release 

Can Most Cancer Really Be Prevented?

(TIME) May 19, 2016 - A new study zeroes in on an answer.
read article 

Overweight Colorectal Cancer Patients Have Higher Survival Rate Than Normal-Weight Patients

(Kaiser Permanente) May 19, 2016 - Overweight colorectal cancer patients were 55 percent less likely to die from their cancer than normal-weight patients who have the disease, according to a new Kaiser Permanente study published today in JAMA Oncology.
read press release 

Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE(R) (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer

( May 19, 2016 - Study to evaluate MM-151 in combination with ONIVYDE plus fluorouracil and leucovorin.
read article 

Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients with Most Appropriate Combination Regimens

(Yahoo! Finance) May 19, 2016 - Merrimack Pharmaceuticals, Inc. announced today the initiation of a biomarker-selected, multi-arm Phase 1 clinical study in metastatic colorectal, non-small cell lung, and head and neck cancers.
read article 

Daratumumab and Ofatumumab Data to Be Presented at 21st Congress of EHA

(Euroinvestor) May 19, 2016 - Daratumumab interim data from Phase III POLLUX study to be presented at EHA; daratumumab Phase III CASTOR data to be presented.
read article 

Castle Biosciences Announces New Clinical Data Presentations at ASCO 2016 Underscoring the Accuracy and Clinical Utility of Gene Expression Profile Test for Cutaneous Melanoma

(Yahoo! Finance) May 19, 2016 - Castle Biosciences, Inc. today announced that several abstracts on the Company’s gene expression profile (GEP) tests for cancer were accepted for poster presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3-7.
read article 

Myriad to Present New Research at the 2016 ASCO Annual Meeting

(NASDAQ) May 18, 2016 - Data demonstrate expanded utility of the MyRisk® hereditary cancer test.
read article 

ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer

(NASDAQ) May 18, 2016 - Data to be presented at the 2016 ASCO annual meeting; company to discuss results with regulators after additional follow up.
read article 

ImmunoGen Reports Efficacy and Safety Data From a 46-Patient Cohort of Mirvetuximab Soravtansine in FRa-Positive Ovarian Cancer

(Stockwatch) May 18, 2016 - ImmunoGen, Inc. today reported the clinical data from a 46-patient Phase 1 cohort evaluating the efficacy and safety of mirvetuximab soravtansine as single-agent therapy for platinum-resistant, folate receptor alpha (FRa)-positive ovarian cancer.
read article 

Immunomedics to Report Updated Results for Sacituzumab Govitecan (IMMU-132) in Breast and Lung Cancers at Clinical Science Symposia of 2016 ASCO Annual Meeting

(Yahoo! Finance) May 19, 2016 - Immunomedics, Inc., today announced that the Scientific Program Committee of the American Society of Clinical Oncology (ASCO) has selected two of the Company’s abstracts for oral presentation at two Clinical Science Symposium Sessions during their 2016 Annual Meeting, scheduled for June 3-7, 2016 at McCormick Place Convention Center in Chicago, Illinois.
read article 

ARIAD Announces Data Presentations at the 2016 ASCO Annual Meeting

(Yahoo! Finance) May 18, 2016 - ARIAD Pharmaceuticals, Inc. today announced that clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, and Iclusig® (ponatinib) will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, June 3 to 7, 2016.
read article 

Array BioPharma Announces Key Data From NRAS-mutant Melanoma and BRAF-mutant Colorectal Cancer ASCO 2016 Presentations

(Array BioPharma) May 18, 2016 - Array BioPharma will present additional data on its late-stage candidates binimetinib and encorafenib in NRAS-mutant melanoma and BRAF-mutant colorectal cancer, respectively, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 3 - 7.
read corporate press release